Vyloy (zolbetuximab)

pCPA File Number: 23017
Negotiation Status:
Under consideration for negotiation
Indication(s):
In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive
Sponsor/Manufacturer:
Astellas Pharma Inc.
CDA-AMC Project Number:
PC0338-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable